Abstract
The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.
Keywords:
COVID-19; SARS-CoV-2; antibodies; coronavirus; humoral immunity; immunofluorescence assay; microneutralisation test; western blotting; whole-genome sequencing.
MeSH terms
-
Adult
-
Antibodies, Viral / blood
-
Asymptomatic Infections
-
Betacoronavirus
-
COVID-19
-
COVID-19 Testing
-
China
-
Clinical Laboratory Techniques
-
Contact Tracing*
-
Coronavirus / genetics*
-
Coronavirus / immunology
-
Coronavirus / isolation & purification*
-
Coronavirus Infections* / diagnosis
-
Coronavirus Infections* / transmission
-
Coronavirus Infections* / virology
-
Female
-
Finland
-
Fluorescent Antibody Technique
-
Humans
-
Immunoglobulin A / blood
-
Immunoglobulin G / blood
-
Immunoglobulin M / blood
-
Neutralization Tests
-
Pandemics*
-
Pneumonia, Viral* / diagnosis
-
Pneumonia, Viral* / transmission
-
Pneumonia, Viral* / virology
-
SARS-CoV-2
-
Severe Acute Respiratory Syndrome / etiology
-
Severe Acute Respiratory Syndrome / immunology*
-
Severe Acute Respiratory Syndrome / virology
-
Severe acute respiratory syndrome-related coronavirus / immunology*
-
Severe acute respiratory syndrome-related coronavirus / pathogenicity
-
Travel*
-
Viral Envelope Proteins
Substances
-
Antibodies, Viral
-
Immunoglobulin A
-
Immunoglobulin G
-
Immunoglobulin M
-
Viral Envelope Proteins